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ABSTRACT
The iDISCO (immunolabeling-enabled three-dimensional imaging of solventcleared organs) method is a quick, inexpensive, and easily adaptable tissue staining and
clearing procedure that allows neuroscientists to study a protein of interest in a whole,
unaltered tissue sample. While the iDISCO method was initially tested and validated for
mice embryos and brains, the current experiment sought to adapt the method for use in
the rat using HIV-1 transgenic (Tg) rat brain tissue. Antibodies for tyrosine hydroxylase
and Iba-1 were validated in the HIV-1 Tg rat and in F344/N control rats using iDISCO.
Confocal images were taken of tyrosine hydroxylase positive neurons in the substantia
nigra area of male and female HIV-1 Tg and F344/N control rats. The HIV-1 Tg female
rat was determined to have the most positive TH staining, followed by the control male,
HIV-1 Tg male, and control female. Viewing the brain as a whole system rather than a
series of individual pieces is the biggest advantage of the whole-brain tissue clearing
iDISCO method.
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CHAPTER 1
INTRODUCTION
1.1 TISSUE CLEARING
Immunohistochemical (IHC) staining is a common procedure used to identify a
target protein in a tissue sample. First implemented in the mid-1900s, and used
continuously since, IHC uses antigen specific antibodies to mark proteins of interest
(Coons et al., 1941; Ramos-Vara, 2005). Most IHC procedures follow a similar
workflow. First, a tissue sample is fixed to preserve the tissue’s morphology (Grizzle,
2009). After fixation, samples can easily be cut into thin sections using a vibratome,
cryostat, or brain matrix. Most traditional IHC procedures call for a tissue width of
between 10-100 µm (West, 2012). Tissue samples are then blocked for endogenous
materials present in the sample. Peroxidase blocking prevents blood cells from interfering
with later imaging, and serum blocking of endogenous antibodies is essential to prevent
cross-reactivity with the secondary antibody. A primary antibody corresponding to the
protein of interest is used, followed by a secondary antibody corresponding to the animal
of origin of the primary antibody. The secondary antibody either fluoresces when in the
presence of a specific wavelength of light or is compatible for use with a permanent
dyeing protocol, such as the avidin-biotin complex method (Ramos-Vara & Miller,
2014). After mounting the sample, positive staining is viewed under a light or florescent
microscope.
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Traditional IHC protocol are generally uncomplicated, inexpensive, versatile, and
are compatible with the powerful statistical procedure of stereology (West, 2012). The
aim of most IHC experiments is to determine localization or quantification of a protein of
interest. However, there are limitations to conventional free-floating or slide-based IHC
that can make analysis using stereology difficult.
A tissue sample must meet strict criteria to be reliably assessed using stereology
(West, 2012). First, conventional free-floating or slide-based IHC procedures involve
dehydration steps and thus, tissues that start out appropriately thick may become too thin
to be used in certain stereological probes. For tissue that is not homogenous, like the
brain, dehydration-induced shrinkage of the sample may occur unevenly (Larsson, 1993).
Second, traditional IHC protocols involve cutting the tissue samples into very thin (10100 µm) slices, which can cause further loss of cells, structures, or proteins of interest.
Because of this loss, the top and bottom of tissue samples are usually neglected in
stereology, and thus, tissue is wasted (West, 2012). Third, important biological structures
must be cut into many pieces to be compatible with traditional IHC protocol. Structures
in pieces can no longer easily be analyzed as a whole, or as a component of a larger
system. Finally, slide-based or free-floating protocols do not usually allow for deep
penetration of the antibodies. Even if an antibody were able to penetrate a thicker sample,
the sample would likely be too optically opaque to allow for the light penetration
necessary for visualization on a microscope (Ariel, 2017).
Tissue clearing offers a solution to the aforementioned limitations of traditional
IHC protocol. A sample that is transparent minimizes the scattering and absorption of
light, which provides cellular level optical access to tissues that are intact (Rocha et al.,
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2019; Richardson & Lichtman, 2015). Tissue clearing techniques turn a tissue transparent
through delipidation, decolorization, and decalcification with the administration of
solvents. Once the refractive index of the tissue sample matches the refractive index of
the chosen imaging medium, the sample will appear completely transparent and can be
properly imaged (Ueda et al., 2020).
Several tissue clearing techniques have been validated for use in the brain:
hydrogel, hydrophilic, and hydrophobic. Hydrogel based techniques, such as CLARITY,
secure biomolecules in the tissue by linking them to acryl-based hydrogels, which
prevents structural damage and loss of proteins (Chung et al., 2013). However, hydrogel
techniques utilize harsh chemicals that have the potential to damage more fragile tissues
or antibodies, and denser tissue samples may not be compatible with some hydrogel
protocol. Certain hydrogel techniques may also require expensive equipment or lead to
tissue expansion. Hydrophilic techniques, like CUBIC and FocusClear, preserve 3D
structure through the formation of hydrogen bonds within the tissue (Susaki, et al., 2014).
Tissue expansion can also occur in certain hydrophilic protocol. The clearing ability of
hydrogel and hydrophilic techniques often does not match that of hydrophobic methods,
which is crucial for denser and thicker tissues (Ueda et al., 2020).
Immunolabeling-enabled three-dimensional imaging of solvent-cleared organs
(iDISCO) is a hydrophobic clearing technique that improves upon previous hydrophobic
techniques by eliminating the shrinkage that can occur (Renier et al., 2014). The iDISCO
procedure removes water from the tissue in the initial dehydration step, thus reducing
light scatter. Tissue is permeabilized during pretreatment to allow deep antibody
penetration. Tissue that has undergone the iDISCO protocol is able to be handled easily
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and can be imaged several times. If properly stored, tissues can still provide images for
up to a year after initial processing. A hydrophobic technique such as iDISCO is
relatively fast, does not require special equipment, and produces a sample that is easy to
handle and store.
Originally, the iDISCO tissue clearing technique was described by Renier et al.
(2014), who extended the utility of the 3DISCO procedure to include mice embryos and
denser, adult organs of mice. The iDISCO technique has been implemented many times
in mice, to great success (Renier et al, 2016; Silvestri et al., 2016). To date, however, the
technique’s full clearing ability has not been as well established in rats (Jing et al., 2018;
Qi et al., 2019). Validation in the rat brain serves as an important advancement, as rats
are used in approximately 50% of neuroscience publications and offer many advantages
over mice due to their larger brain size and behavioral differences (Ellenbroek & Youn,
2016).
The first goal of the present experiment was to therefore demonstrate the full
clearing ability of iDISCO in a commonly used species of laboratory rat, the F344/N
Fischer rat. Because of their utility in neuroscience research, transgenic models of
infectious diseases have been created in the species, such as the HIV-1 transgenic (Tg)
rat.
1.2 HIV
The HIV-1 Tg rat was created on the F344/N background and provides
researchers with a non-infectious animal model for HIV-1 (Reid et al., 2001). The HIV-1
provirus present in the transgenic rats has a functional deletion of two (gag and pol) of
the three (gag, pol, and env) structural genes necessary for production of viral particles.
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Despite these deletions, the genes of the provirus encoding for regulatory and accessory
proteins, such as tat, remain functional. The HIV-1 Tg rat is a non-infectious model for
HIV-1 induced viral protein exposure on brain function and overt behavior, which results
in a model that is useful for studying the effect of viral proteins in the absence of active
infection (Bertrand et al., 2018; Reid et al. 2001; Vigorito et al. 2015; McLaurin et al.,
2018).
There are an estimated 37.9 million adults living with HIV, with 1.7 million new
HIV infections occurring in 2018 alone (UNAIDS, 2019). To control the infection,
individuals with the virus are often prescribed combination antiretroviral therapy (cART),
a combination of fusion inhibitors, nucleotide and non-nucleotide reverse transcriptase
inhibitors, integrase inhibitors, CCR5 antagonists, and protease inhibitors meant to
suppress viral replication and block new infection (Bertrand et al., 2015; Sengupta &
Siliciano, 2018). cART suppresses the virus’s ability to replicate, which reduces the
amount of circulating virus that is immune to treatment (Sengupta & Siliciano, 2018;
Smyth et al., 2012). HIV-1 can enter a state of latency in some infected cells (Sengupta &
Siliciano, 2018). Despite the suppression of replication from cART, latent HIV infection
is still able to release HIV-1 neurotoxic proteins through astrocytes and microglia
(Bertrand et al., 2015; Bertrand et al., 2014). Even transient exposure to these proteins
may be enough to trigger a cascade of cellular events, such as apoptosis or inflammatory
responses, that could lead to dendritic or synaptic loss (Aksenova et al., 2006; Bertrand et
al., 2014).
Dysregulation of the dopaminergic system associated with HIV-1 has been well
established in both human, clinical populations (Silvers et al., 2006; Gelman et al., 2006;
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Kumar et al., 2011) and transgenic animal models (Lee et al., 2014; Javadi-Paydar et al.,
2017; Bertrand et al., 2018). HIV-1 viral proteins Tat and gp120 have been theorized to
directly affect the dopaminergic system, leading to behavioral and motivational
alterations (Bennet et al., 1995; Fitting et al., 2015; Moran et al., 2012; Bertrand et al.,
2018). Previous studies in the HIV-1 Tg rat have shown that dopaminergic impairment is
greater in HIV-1 Tg animals when compared to controls; sex differences are also present,
with HIV-1 Tg female rats being the most impaired group in both chemical and
behavioral measures (Denton et al., 2019; McLaurin et al., 2017).
Tyrosine hydroxylase (TH) is the rate-limiting enzyme in the primary pathway of
dopamine synthesis, and its detection is often used to draw conclusions about an
organism’s dopaminergic system. Decreased TH immunostaining in the striatum and
substantia nigra areas indicate an enzymatic deficit in dopaminergic projections (Daubner
et al., 2011). TH has previously been studied in the HIV-1 Tg rat using traditional IHC
methodology (Goulding et al., 2019; Moran et al., 2012). At 8 months, male HIV-1 Tg
rats were found to have significantly less TH+ staining when compared to controls; this
same effect was not seen in younger (2-5 month old) rats (Goulding et al., 2019). In the
present study, TH is used as an enzymatic marker for dopamine synthesis. It is
hypothesized that HIV-1 Tg rats will show more TH impairment than controls, with HIV1 Tg females showing the greatest impairment. The TH antibody used is rabbit
polyclonal, and labels 62kDa, which corresponds to tyrosine hydroxylase (AB152,
Millipore Sigma).
Microglia are a type of glial cell responsible for responding to cellular level
threats that occur in the brain (Frank et al., 2019; Crotti et al., 2016). “Resting” microglia
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sample the environment to look for threats with long, branching processes, while
“activated” microglia will seek and destroy bacteria or foreign cells (Nimmerjahn et al.,
2005). Microglia will activate in response to various stressors in the brain, such as
physical trauma, seizure, or infections such as HIV-1 (Frank et al., 2019; Goulding et al.,
2019; Rowson et al., 2016; Vera et al., 2016; Liu et al., 2018). Activation of microglia
causes inflammation, which can induce a variety of behavioral, endocrine, and neural
responses in multiple brain regions (Banks et al., 2015; Guillemin et al., 2004). Ionized
calcium-binding adapter molecule 1 (Iba1) is a protein present in microglia that increases
with activation (Ohsawa et al., 2004). Due to the interaction between the HIV-1 virus and
microglia, and the effects of inflammation on the brain, microglia are an important target
of study (Hauser & Knapp, 2015). The present study seeks to confirm the compatibility
of an Iba1 antibody with the iDISCO clearing method for use in the HIV-1 Tg rat. The
Iba1 antibody used is rabbit polyclonal, and was raised against a synthetic peptide
corresponding to the Iba1 carboxy-terminal sequence (019-19741, FUJIFILM Wako).
The present experiment has three objectives. The first, and main, objective is to
establish the validity of the iDISCO tissue clearing technique in F344/N and HIV-1 Tg
rat brain tissue. The second objective is to validate two antibodies (TH and Iba1) for use
in rat brain tissue. The third objective is to investigate the levels of TH+ staining in male
and female HIV-1 Tg and F344/N control rats to more clearly understand the impact of
HIV-1 associated viral protein exposure on dopamine production throughout the nigrastriatal and mesocorticolimbic dopamine systems. Using the iDISCO tissue clearing
technique as a guide, TH and Iba1 antibodies were administered to male and female
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F344/N control and HIV-1 Tg rat brains, with TH serving as a marker for dopamine
production, and Iba1 marking for activated microglia.
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CHAPTER 2
MATERIALS AND METHODS
2.1 ETHICS STATEMENT
The present research was conducted in accordance with the recommendations
listed in the Guide for the Care and Use of Laboratory Animals from the National
Institutes of Health. All rats used were housed in an AAALAC-accredited facility, with
all procedures approved by the University of South Carolina Institutional Animal Care
and Use Committee (IACUC).
2.2 SUBJECTS
One HIV-1 Tg female, one HIV-1 Tg male, one F344/N control female, and one
F344/N control male were used for the present study. Dames to the subjects were
obtained from Envigo (Indianapolis, IN). All rats were housed under conditions targeted
to 21° ± 2 °C, 50% ±10% relative humidity with a 12 hour light-dark cycle. Subjects
were housed with their littermates until the day of weaning.
2.3 SAMPLE PREPARATION
Ingredients for all solutions can be found in Appendix A. Supplier information for
each chemical can be found in Appendix B. On the day of weaning (approximately
postnatal day 21 to 24), a rat from a litter meeting proper transgene and sex criteria was
selected for sacrifice. Rats were deeply anesthetized using sevoflurane. The rat was
considered sufficiently anesthetized when it failed to respond to toe and tail pinch. In a
fume hood, rats were laid supinely, and a lateral incision was made through the
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abdominal wall beneath the rib cage to prepare for perfusion. A cut was made up through
the bottom of the rib cage to the collarbone, cutting the diaphragm along the length of the
rib cage. The left ventricle was pierced with a 23-gauge needle attached to a perfusion
pump. After cutting open the right atrium, the perfusion began. Approximately 75mL of
room temperature (RT) 100mM (1X) phosphate buffered saline (PBS) was used to flush
the vasculature. The transcardial perfusion was continued with approximately 100mL of
4% paraformaldehyde (PFA) buffered in 1X PBS. Once the rat was fully perfused, the
brain was removed from the skull. Meninges were removed. Each brain was sliced
sagittally using a razor blade into sections approximately 3mm in width. Each section
was fixed in 4% PFA in 1X PBS in a sealed, 5mL plastic tube overnight at 4° C on a
shaker. All steps were performed in fully filled, closed tubes to avoid oxidation of the
samples. The next day, sections continued to fix at RT on a shaker for 1 additional hour.
Sections were placed in a new 5mL tube and were washed 3 times with 1X PBS at RT for
30 minutes.
2.4 METHANOL PRETREATMENT
Samples were incubated in increasing concentrations of methanol for 1 hour per
concentration at RT. The concentrations used were 20% methanol/80% deionized water,
40% methanol, 60% methanol, 80% methanol, and 100% methanol twice. Each sample
was then chilled in fresh 100% methanol at 4° C for approximately 10 minutes. Samples
were then incubated overnight in a 66% dicholoromethane/33% methanol solution at RT
with shaking. Each sample was washed with methanol at RT for 30 minutes, twice.
Samples were then chilled in 100% methanol at 4° C for approximately 10 minutes.
Samples were bleached in chilled, freshly prepared 5% hydrogen peroxide/95% methanol
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overnight at 4° C. Samples were then rehydrated in decreasing concentrations of
methanol for 1 hour per concentration at RT. The concentration order used was 80%
methanol/20% deionized water, 60% methanol, 40% methanol, 20% methanol, followed
by a 1 hour incubation of 1X PBS. Samples were washed in PTx.2 for 1 hour at RT,
twice.
2.5 IMMUNOLABELING
Samples were incubated in permeabilizing solution for 2 days at 37°C in a closed,
incubator water bath. After removal from the permeabilizing solution, samples were
incubated in blocking solution for 2 days at 37°C in a closed, incubator water bath. After
2 days, one hemisphere from each animal was incubated with the tyrosine hydroxylase
(TH) primary antibody at a concentration of 1:100 (AB152, Millipore Sigma) in 92%
PTwH/5% DMSO/3% goat serum for 7 days at 37°C in a closed, incubator water bath.
The other hemisphere was incubated with the Iba1 primary antibody (019-19741,
FUJIFILM Wako) at a concentration of 1:200 in the same solution and conditions. After
7 days, samples were washed in PTwH 5 times at 1 hour per wash, and then stored in
PTwH at RT overnight. The next day, samples were incubated in Alexa Fluor Plus 647
(A32733, Invitrogen) secondary antibody in 97% PTwH/3% goat serum for 7 days at
37°C in a closed, incubator water bath. Goat serum was used because it corresponded
with the secondary antibody chosen for labelling. Samples were washed in PTwH 5 times
at 1 hour per wash, and then stored in PTwH at RT overnight.
2.6 CLEARING
Samples were incubated in increasing concentrations of methanol for 1 hour per
concentration at RT. The concentrations used were 20% methanol/80% deionized water,
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40% methanol, 60% methanol, 80% methanol, and 100% methanol. The samples were
then incubated overnight in fresh 100% methanol at RT. After this, samples were
incubated in 66% DCM/33% methanol for 3 hours, with shaking, at RT. Samples were
then placed in DBE and left in a dark place at RT until ready for mounting. Samples were
mounted after they were clear.
2.7 MOUNTING
3D printed chambers were ordered using the 3D models found on the idisco.info
website. Chambers were printed using Visijet M3 Crystal resin, as it is will not degrade
in the presence of DBE. Chambers with a depth of 3mm were used. Chambers were
secured to microscope slides using Kwik-sil epoxy (VWR), which cures in the presence
of DBE. This epoxy also does not form a permanent bond to the chamber, so samples are
able to be remounted and reimaged. Samples were placed in the space within the
chamber, and the chamber was filled with DBE. A 0.17 mm coverslip was placed over
the chamber, and light pressure was applied to the slide to flatten the sample and form a
seal with the chamber. While still applying pressure, the edges of the coverslip were
sealed with Kwik-sil epoxy. Pressure was applied for 5 minutes until the epoxy cured.
After curing, the chamber was rotated to allow air bubbles to escape from the filling inlet.
Additional DBE was added into the chamber via a syringe to ensure that the sample was
not exposed to air. The filling inlet was sealed with epoxy.
2.8 IMAGING
Images were obtained using a Nikon TE-2000E confocal microscope (Nikon,
Tokyo, Japan) running Nikon’s EZ-C1 software (version 3.81b). Tyrosine hydroxylase
excitation was achieved utilizing a HeNe laser set to emit at 632 nm. The detector was set
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to 650 nm. Images were obtained at 4x and 10x magnification, using the medium and
large pinhole sizes provided by the EZ-C1 software. The 650LP gain for all images was
set to 7.50 B. The substantia nigra, nucleus accumbens, prefrontal cortex, and ventral
tegmental areas were identified and imaged in each rat when possible. Approximately 20
images were obtained per animal.
2.9 ANALYSIS
Out of the approximately 20 images obtained for each animal, the 4 images per
animal which displayed the most positive fluorescence were chosen. Each animal was
ranked from greatest to least TH expression. The ranking was first established by the
primary researcher, but to avoid potential bias, three other researchers who were blind to
condition were given criteria for positive staining and were also allowed to rank the
overall TH expression of each animal. Four representative images were obtained for each
animal used. Figure 2.1 shows a representative confocal image for TH in the substantia
nigra region shown to all other raters. Raters blind to condition were shown this image,
along with the description that marker “A” represents dense, positive staining, marker
“B” represents sparse positive staining, and marker “C” represents tissue that is not
positively stained. Raters were instructed to consider the overall staining present in the 4
images.
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Figure 2.1: A representative confocal image from the HIV-1 Tg female (4x
magnification). “A” represents dense TH staining, “B” sparse TH staining, and
“C” no TH staining.
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CHAPTER 3
RESULTS
F344/N and HIV-1 Tg rat brain tissues were able to be fully cleared by the present
study’s adjusted tissue clearing protocol (Figure 3.1). Increasing the length of the
antibody incubation time allowed the antibody to fully penetrate the thick tissue.
Changing the blocking serum to correspond according to the primary antibody reduced
background staining. There was no noticeable difference in clearing between HIV-1 Tg
tissue and F344/N control tissue.
TH and Iba1 staining were both compatible with the tissue clearing method used
and had no noticeable detrimental interactions with the HIV-1 provirus. Figure 3.2 shows
typical morphology of a TH positive neuron, with a large soma and several branching
processes (Roostalu et al., 2019). Figure 3.3 shows Iba1 stained activated microglia,
which have small cell bodies and shorter extending processes (Ransohoff & Cardona,
2010). Because the expected cell morphology was observed, the antibodies were
considered to be successful in staining and compatible with the protocol.
Four representative images were chosen for each animal used. Blinded rankings
were in 100% agreeance with the non-blinded ranking. The order of most to least TH+
staining was determined to be as follows: HIV-1 Tg female (Figure 3.4), F344/N control
male (Figure 3.5), HIV-1 Tg male (Figure 3.6), F344/N control female (Figure 3.7).
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Figure 3.1: A cleared brain tissue sample in DBE.
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Figure 3.2: TH positive neurons (20x magnification, F344/N control male).

17

Figure 3.3: Iba1 positive microglia (20x magnification, F344/N control male).
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Figure 3.4: Four representative images of TH+ staining in the HIV-1 Tg female (4x
magnification).
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Figure 3.5: Four representative images of TH+ staining in the F344/N male (4x
magnification).
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Figure 3.6: Four representative images of TH+ staining in the HIV-1 Tg male (4x
magnification).
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Figure 3.7: Four representative images of TH+ staining in the F344/N female (4x
magnification).
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CHAPTER 4
DISCUSSION
The immunostaining findings from the present study partially supported the
original hypothesis. HIV-1 Tg females were determined to have the most TH+ staining,
followed by F344/N males, HIV-1 Tg males, and F344/N females. Previous research has
shown that TH staining in the substantia nigra is reduced in HIV-1 Tg male rats, with
more TH loss seen over time (Webb et al., 2010; Goulding et al., 2019). This finding is
also present in male-dominated studies of adult HIV-1 infected human brain tissue
(Gelman et al., 2006). In the present study, this same effect was also seen, with the
F344/N control male rat showing more TH positive staining when compared to the HIV-1
Tg male.
When compared to their male counterparts, HIV-1 Tg females present delayed
task acquisition, less accurate signal detection, decreased dopamine release, impaired
temporal processing, and decreased locomotor activity (McLaurin et al., 2017; Denton et
al., 2019). Estrogen and phytoestrogens have been shown to prevent neuronal damage
caused by Tat, reverse F-actin loss, and reduce HIV-1 associated motor and cognitive
dysfunction (Adams et al. 2010; Bertrand et al. 2015; Wallace et al. 2006). Sex
differences have also been observed in human clinical populations, where HIV-1 positive
women have been shown to have higher levels of neurocognitive impairment than HIV-1
positive men (Royal et al., 2016; Sundermann et al., 2019). Based on this prior research,
it was expected that the traditionally impaired HIV-1 Tg females would also have the
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lowest overall TH levels. This was not the case, as the HIV-1 Tg female was determined
to have the most positive TH staining out of the four animals tested. The current data
suggest the presence of a sex by genotype interaction in relation to TH.
TH is traditionally used as an indicator of dopamine production. However, it is
not entirely correct to make the assumption that more TH always indicates more
dopamine production. TH is the rate-limiting enzyme that catalyzes the hydroxylation of
tyrosine to L-DOPA, which can then be converted to dopamine using aromatic amino
acid decarboxylase (Flatmark, 2000). TH is activated when the amount of
neurotransmitter required increases at a catecholaminergic synapse, and activation is
sustained until the requirement is lessened. TH is inactivated via feedback inhibition from
the catecholamine neurotransmitters it helps create (Daubner et al., 2011). Previous
research has shown that TH concentration and activation can even be increased following
the destruction of catecholaminergic terminals, as if to compensate for the loss (Zigmond
et al., 1984; Acheson et al., 1981). The increased TH levels seen in the female HIV-1 rat
of the present study are possibly part of the compensatory action of TH in response to
lowered dopamine in the system (Iuvone, 1983). Metabolite level differences have been
previously been observed in HIV-1 positive patients when compared to controls
(Ghannoum et al., 2013). With this in mind, an important consideration is the role that the
HIV-1 virus might have in affecting other chemicals in the chain of dopamine synthesis
such as L-DOPA, DOPA decarboxylase, or phenylalanine hydroxylase.
The present data have several severe limitations. Firstly, it cannot be ignored that
each sex and genotype was represented by only one subject, which opens up the
possibility that a non-representative subject happened to be randomly chosen. Thus,
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while preliminary differences exist in this small sample size, a larger sample is necessary
to confirm the present observed differences. The data presented here are observational in
nature, and are not backed by any quantitative analysis. Quantitative analyses are limited
by the tools currently available for the rat brain. Currently, investigative tools such as
ClearMap exist to analyze cleared tissue of the mouse brain, but 3D rat brain atlases are
still in development (Renier et al., 2016; Branch et al., 2019).
For the present study, rats were processed on the day of weaning (approximately
day 21 of life). While it is not proper to make a direct comparison between rat age and
the corresponding age of a human, a rat of weaning age is closer developmentally to a
pre-pubescent human than to an adult (Sengupta, 2013). Rats do not reach sexual
maturity until approximately 7 weeks of age, which means that female rats at weaning
have not yet established their estrous cycles (Blunn, 1939). It is possible that female HIV1 Tg rats have more TH than control females before sexual maturity, but more research
would be needed to consider this possibility. As women account for roughly half of
human HIV-1 cases, and sex differences are consistently observed in HIV-1 Tg rats, sex
effects and interactions should continue to be investigated down to the molecular level
(UNAIDS, 2019).
The tissue clearing results from the present study exhibited that the hydrophobic
iDISCO clearing method is viable in large sections of both F344/N control and HIV-1 Tg
rat brain tissue. The present protocol differs in a few important ways from the original by
Renier, et al. (2014). Firstly, overall reduction of background staining was achieved by
specifying the blocking serum used in the blocking, primary, and secondary antibody
steps. Clearer images, reduced background signal, and more accurate staining was
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achieved by using the serum corresponding to the secondary antibody (in this case, goat),
instead of the donkey serum used in the original iDISCO protocol. Incubation time across
the protocol was increased to account for larger tissue size and differing tissue density,
which allowed for complete antibody penetration. TH and Iba1 antibodies were both
validated for use with this method and in F344/N control and HIV-1 Tg rat brain tissue.
There are a few important considerations and limitations to the present tissueclearing protocol. Despite the desire to leave the brain tissue intact, cutting the tissue to a
smaller size is necessary due to the current physical limitations of the iDISCO imaging
chambers. Maximum tissue thickness is also limited by the physical limitations of the
confocal microscope; chambers that exceed a certain vertical height will collide with the
lenses of the confocal microscope, and extremely thick tissues may not be able to be
properly focused. While tissue clearing provides the advantage of imaging thicker tissue
sections, it does truly leave the tissue sections clear, and thus, devoid of many natural
landmarks.

26

CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS
Overall, the iDISCO technique is an extremely versatile, easy to implement, and
low cost procedure with a growing list of validated antibodies. The present study
provides continued evidence that the iDISCO tissue clearing technique is viable in brain
tissues of the rat, has no discernible detrimental interactions with HIV-1 viral proteins,
and is compatible with TH and Iba1 antibodies. Now, new investigative research
questions can be explored utilizing this tissue clearing technique.
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APPENDIX A
SOLUTION RECIPES
PTx.2 (1L)
900mL H2O
100mL PBS 10X
2mL TritonX-100
PTwH (1L)
900mL H2O
100mL PBS 10X
2mL Tween-20
1mL of 10mg/mL Heparin stock solution
Permeabilization Solution (500mL)
400mL PTx.2
11.5g of Glycine
100mL of DMSO
Blocking Solution (50mL)
42mL PTx.2
3mL of Goat Serum
5mL of DMSO
Tyrosine Hydroxylase Primary
93% PTwH
5% DMSO
3% Goat Serum
1:100 Tyrosine hydroxylase primary antibody
Iba1 Primary
93% PTwH
5% DMSO
3% Goat Serum
1:200 Iba1 primary antibody
Secondary Antibody (for both TH and Iba1)
97% PTwH
3% Goat Serum
1:100 Anti-rabbit secondary antibody

38

APPENDIX B
SUPPLIER INFORMATION
Table B.1: Supplier information and catalog numbers.
Name of Material/Equipment

Company

Catalog Number

DBE
DCM
DMSO
Glycine
Goat anti-rabbit Alexa Fluor Plus 647
Goat serum
Heparin
Iba1 primary antibody
Kwik-sil epoxy
Methanol
PBS
Perfusion pump
PFA
TritonX-100
Tween-20
Tyrosine hydroxylase primary antibody

Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
Fisher Chemical
Invitrogen
Sigma Life Science
Acros Organics
FUJIFILM Wako
VWR
Sigma-Aldrich
Fisher Bioreagents
VWR
Sigma-Aldrich
Fisher Bioreagents
Fisher Bioreagents
Millipore Sigma

108014-1KG
270997-100mL
472301-1L
G46-500
A32733
G9023-10mL
41121-0010
019-19741
MSPP-KWIK-SIL
34860-1l-R
BP2944-100
70730-062
158127-3KG
BP151-500
BP337-500
AB152
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